Kezar Life Sciences, Inc. (KZR) financial statements (2020 and earlier)

Company profile

Business Address 4000 SHORELINE COURT, SUITE 300
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments78107
Cash and cash equivalents1524
Short-term investments6383
Prepaid expense22
Other current assets10
Total current assets:81110
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment45
Other noncurrent assets00
Total noncurrent assets:85
TOTAL ASSETS:90115
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities53
Accounts payable10
Accrued liabilities43
Debt1 
Deferred rent credit 0
Other liabilities00
Total current liabilities:63
Noncurrent Liabilities
Long-term debt and lease obligation5 
Operating lease, liability5
Liabilities, other than long-term debt 3
Deferred rent credit 3
Total noncurrent liabilities:53
Total liabilities:116
Stockholders' equity
Stockholders' equity attributable to parent78109
Common stock00
Additional paid in capital163158
Accumulated other comprehensive loss(0)(0)
Accumulated deficit(84)(49)
Total stockholders' equity:78109
TOTAL LIABILITIES AND EQUITY:90115

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Operating expenses(37)(25)
Operating loss:(37)(25)
Loss before gain (loss) on sale of properties:(37)(25)
Other undisclosed net income22
Net loss available to common stockholders, diluted:(35)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(35)(23)
Comprehensive loss:(35)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0(0)
Comprehensive loss, net of tax, attributable to parent:(35)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: